View Clinical Trial (Medical Research Study)

A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia - NCT00523302-29425(Clinical Trial 181763)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Charleston
State:  
SC
Zip Code: 29425
Conditions: Major Depression - Fibromyalgia
Purpose: In this pilot study, the PI proposes to include 20 African American participants with Fibromyalgia to explore the effect of r TMS on pain and depressive symptoms. The focus on African Americans is due to the mandate from the funding source (internal), as well as possible higher prevalence of FM in AA women. If recruitment is slow, the PI proposes to open up the study to other groups. Twenty subjects will be randomized to either sham or active TMS condition. Inclusion/exclusion criteria are well thought out and seem appropriate. mTreatments will be administered at IOP 5 times/wk with each session lasting 20 minutes. Pain intensity and unpleasantness will be measured pre and post each TMS session using three different pain evaluation paradigms. GCRC resource is mainly requested for two blood draws pre and post first TMS session. The blood samples will be used to measure inflammatory cytokines IL-1, IL-6, AND IL-8. The main aim is to ascertain feasibility of the study and secondary aim is to gather information on variability in response for power analysis for future larger study. The introduction and rationale (including pain evaluation, and methods relating to TMS) are clearly presented. Use of GCRC resources seem appropriate.
Study summary:
Criteria: Inclusion Criteria: - age 18-80, - meet ACR criteria for FM for more than 6 months, - may or may not have a diagnosis of major depressive disorder (not bipolar) past or present, - Current major depressive episode must be without psychotic features - Not be on medication known to increase risk of TMS-induced seizures - No prescription medication changes in the previous 4 weeks with agreement not to change during the treatment course (2 weeks) and 2 weeks thereafter - No history of epilepsy or stroke or recent head trauma (LOC > 5 minutes) within the past 6 months - African Americans will be initially sought out for study, however the recruitment may extend to include Caucasian and Hispanic subjects to carry out the study. Exclusion Criteria: - Primary, current diagnosis of schizophrenia - Other (non-mood disorder) psychosis - Mental retardation - Substance dependence or abuse within the past 6 months (except nicotine) - Psychotic features in this episode, dementia, or delirium - Contraindication to rTMS - Increased intracranial pressure - Brain surgery, or head trauma with loss of consciousness for > 15 minutes - Implanted electronic device - Metal in the head, or pregnant - Has an active autoimmune, endocrine, viral, or vascular disorder affecting the brain or unstable cardiac disease - Uncontrolled hypertension, or severe renal or liver insufficiency - Unstable and active suicidal intent or plan - History of attempt requiring medical hospitalization within in the past 6 months - -currently an involuntary inpatient on a psychiatric ward.
Study is available at: Medical University of South Carolina
Charleston, SC 29425
United States

Primary Contact:
E. Baron Short, MD
Email: shorteb@musc.edu
Phone: (843) 792-0199
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.